Alexopoulos P, Thierjung N, Grimmer T, Ortner M, Economou P, Assimakopoulos K et al (2018) Cerebrospinal fluid BACE1 activity and sAβPPβ as biomarker candidates of Alzheimer’s disease. Dement Geriatr Cogn Disord 45:152–161. https://doi.org/10.1159/000488481

Article  CAS  PubMed  Google Scholar 

Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K et al (2009) The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 182:340–346. https://doi.org/10.4049/jimmunol.182.1.340

Article  CAS  PubMed  Google Scholar 

Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y et al (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3:84ra43. https://doi.org/10.1126/scitranslmed.3002254

Article  CAS  PubMed  Google Scholar 

Bettcher BM, Tansey MG, Dorothee G, Heneka MT (2021) Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. Nat Rev Neurol 17:689–701. https://doi.org/10.1038/s41582-021-00549-x

Article  PubMed  PubMed Central  Google Scholar 

Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE et al (2022) Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. PLoS Pathog 18:e1010453. https://doi.org/10.1371/journal.ppat.1010453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148–160. https://doi.org/10.1038/s41583-019-0132-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calabrese EJ (2001) Amyloid beta-peptide: biphasic dose responses. Crit Rev Toxicol 31:605–606. https://doi.org/10.1080/20014091111857

Article  CAS  PubMed  Google Scholar 

DeMarshall CA, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL et al (2016) Detection of Alzheimer’s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) 3:51–62. https://doi.org/10.1016/j.dadm.2016.03.002

Article  PubMed  Google Scholar 

Deng J, Hou H, Giunta B, Mori T, Wang Y-J, Fernandez F et al (2012) Autoreactive-Aβ antibodies promote APP β-secretase processing. J Neurochem 120:732–740. https://doi.org/10.1111/j.1471-4159.2011.07629.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diamond B, Honig G, Mader S, Brimberg L, Volpe BT (2013) Brain-reactive antibodies and disease. Annu Rev Immunol 31:345–385. https://doi.org/10.1146/annurev-immunol-020711-075041

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S et al (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233–243. https://doi.org/10.1016/S1474-4422(13)70014-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV et al (2020) Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med 26:1256–1263. https://doi.org/10.1038/s41591-020-0938-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr 21:672–687. https://doi.org/10.1017/S1041610209009405

Article  PubMed  Google Scholar 

Fillit H, Hess G, Hill J, Bonnet P, Toso C (2009) IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73:180–185. https://doi.org/10.1212/WNL.0b013e3181ae7aaf

Article  CAS  PubMed  Google Scholar 

Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R et al (2022) The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 23:53–66. https://doi.org/10.1038/s41583-021-00533-w

Article  CAS  PubMed  Google Scholar 

Fuller JP, Stavenhagen JB, Teeling JL (2014) New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Front Neurosci 8:235. https://doi.org/10.3389/fnins.2014.00235

Article  PubMed  PubMed Central  Google Scholar 

Hansen N, Malchow B, Zerr I, Stocker W, Wiltfang J, Timaus C (2021) Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort. J Neural Transm (Vienna) 128:357–369. https://doi.org/10.1007/s00702-021-02316-0

Article  CAS  PubMed  Google Scholar 

Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 51:783–786. https://doi.org/10.1002/ana.10208

Article  CAS  PubMed  Google Scholar 

Jian JM, Fan DY, Tian DY, Cheng Y, Sun PY, Tan CR et al (2022) Naturally-occurring antibodies against Bim are decreased in Alzheimer’s disease and attenuate AD-type pathology in a mouse model. Neurosci Bull. https://doi.org/10.1007/s12264-022-00869-y

Article  PubMed  PubMed Central  Google Scholar 

Jiao SS, Bu XL, Liu YH, Zhu C, Wang QH, Shen LL et al (2016) Sex dimorphism profile of Alzheimer’s disease-type pathologies in an app/ps1 mouse model. Neurotox Res 29:256–266. https://doi.org/10.1007/s12640-015-9589-x

Article  CAS  PubMed  Google Scholar 

Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ et al (2015) Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A 112:5225–5230. https://doi.org/10.1073/pnas.1422998112

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin WS, Shen LL, Bu XL, Zhang WW, Chen SH, Huang ZL et al (2017) Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 134:207–220. https://doi.org/10.1007/s00401-017-1721-y

Article  CAS  PubMed  Google Scholar 

Kocurova G, Ricny J, Ovsepian SV (2022) Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases. Theranostics 12:3045–3056. https://doi.org/10.7150/thno.72126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76:1485–1491. https://doi.org/10.1212/WNL.0b013e318217e7a4

Article  CAS  PubMed  Google Scholar 

Liu L, Martin R, Kohler G, Chan C (2013) Palmitate induces transcriptional regulation of BACE1 and presenilin by STAT3 in neurons mediated by astrocytes. Exp Neurol 248:482–490. https://doi.org/10.1016/j.expneurol.2013.08.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YH, Bu XL, Liang CR, Wang YR, Zhang T, Jiao SS et al (2015) An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation 12:153. https://doi.org/10.1186/s12974-015-0379-4

Article  CAS